Last reviewed 2026-04-19 · How we verify

HT-001 0.5% Topical Gel

Hoth Therapeutics, Inc. · Phase 2 active Small molecule

HT-001 0.5% Topical Gel is a Small molecule drug developed by Hoth Therapeutics, Inc.. It is currently in Phase 2 development.

At a glance

Generic name	HT-001 0.5% Topical Gel
Sponsor	Hoth Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HT-001 0.5% Topical Gel CI brief — competitive landscape report
HT-001 0.5% Topical Gel updates RSS · CI watch RSS
Hoth Therapeutics, Inc. portfolio CI

Frequently asked questions about HT-001 0.5% Topical Gel

What is HT-001 0.5% Topical Gel?

HT-001 0.5% Topical Gel is a Small molecule drug developed by Hoth Therapeutics, Inc..

Who makes HT-001 0.5% Topical Gel?

HT-001 0.5% Topical Gel is developed by Hoth Therapeutics, Inc. (see full Hoth Therapeutics, Inc. pipeline at /company/hoth-therapeutics-inc).

What development phase is HT-001 0.5% Topical Gel in?

HT-001 0.5% Topical Gel is in Phase 2.

Manufacturer: Hoth Therapeutics, Inc. — full pipeline
Compare: HT-001 0.5% Topical Gel vs similar drugs
Pricing: HT-001 0.5% Topical Gel cost, discount & access